The Role of Statins in Cutaneous Wound Healing
他汀类药物在皮肤伤口愈合中的作用
基本信息
- 批准号:8324546
- 负责人:
- 金额:$ 20.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-25 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntimicrobial EffectBacterial InfectionsCholesterolClinicalCoenzyme ACollagenCommunitiesCutaneousDataDepositionDiseaseDoseElderlyEnzyme-Linked Immunosorbent AssayExperimental ModelsFamily suidaeGlucocorticoid ReceptorGoalsGranulation TissueHealedHydroxyl RadicalHyperlipidemiaImpairmentIn VitroIncidenceIndividualInfiltrationInflammatoryInflammatory ResponseKnowledgeLeadLearningMeasuresMediatingModelingMolecularMorbidity - disease rateNuclearObesityOxidoreductasePainPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationProcessRegulationResearchRoleSiteSkinSpecimenSterolsTestingTherapeutic UsesThickTopical applicationWound HealingWound Infectionangiogenesisantimicrobialbasecytokinediabeticexperiencefarnesyl pyrophosphatehealinghigh riskimprovedin vivoin vivo Modelinhibitor/antagonistinsightkeratinocytemacrophagemethicillin resistant Staphylococcus aureusmevalonatemigrationneutrophilnovel therapeutic interventionnovel therapeuticspre-clinicaltissue repairwound
项目摘要
DESCRIPTION (provided by applicant): Hyperlipidemia and obesity are well known factors that inhibit wound healing. Conversely, statins, the 3- hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that lower circulating cholesterol levels improve tissue repair. Recently, we have identified molecular mechanism by which statins accelerate wound healing. We found that statins promote wound healing, via blocking the synthesis of Farnesyl pyrophosphate (FPP), an important branch-point intermediate in the mevalonate pathway, essential for synthesis of sterols and isoprenylated cellular metabolites leading to cholesterol synthesis. FPP inhibits keratinocyte migration in vitro and wound healing ex vivo by acting as an anti-inflammatory agent, i.e. a bona fide agonist for glucocorticoid receptor (GR), whereas statins reverse this effect. Therefore, we hypothesize that statins may accelerate wound healing by modulating the inflammatory response. This hypothesis will be tested using topical statins on hyperlipidemic and healthy (normolipidemic) porcine wound healing model in vivo. Once an optimal topical dose of statins is determined (Aim 1) we will determine the effects of statins on the inflammatory response by measuring levels of pro- and anti-inflammatory cytokines, GR- phosphorylation as well as neutrophil and macrophage infiltration in hyperlipidemic and normolipidemic porcine wound model (Aim 2A). Recently, statins were found to have anti-microbial effect. Bacterial infection is one of the most common complications of wound healing, known to inhibit this process. Thus, we will also test if topical statins alone or in combination with systemic statins, accelerate wound healing of bacterially-infected wounds (Aim 2B). The high impact of proposed study is multi-factorial: 1) it will provide a validated in vivo experimental models to study cutaneous wound healing and infection related to obesity and high cholesterol levels; 2) develop pre- clinical evidence for potential topical use of statins to treat wound healing disorders and 3) provide new insights into the mechanism by which statins may impact healing ability of wounds in patients who are using them systemically.
描述(由申请人提供):高血压和肥胖是抑制伤口愈合的众所周知的因素。相反,他汀类药物,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,降低循环胆固醇水平,改善组织修复。最近,我们已经确定了他汀类药物加速伤口愈合的分子机制。我们发现,他汀类药物通过阻断焦磷酸法呢酯(FPP)的合成促进伤口愈合,FPP是甲羟戊酸途径中的重要分支点中间体,对于甾醇和异戊二烯化细胞代谢物的合成至关重要,从而导致胆固醇合成。FPP通过作为抗炎剂,即糖皮质激素受体(GR)的真正激动剂,抑制体外角质形成细胞迁移和离体伤口愈合,而他汀类药物逆转这种作用。因此,我们假设他汀类药物可以通过调节炎症反应来加速伤口愈合。将使用局部他汀类药物对高脂血症和健康(正常脂血症)猪伤口愈合模型进行体内试验。一旦确定了他汀类药物的最佳局部剂量(目的1),我们将通过测量高脂血症和正常脂血症猪伤口模型中促炎细胞因子和抗炎细胞因子、GR-磷酸化以及嗜中性粒细胞和巨噬细胞浸润的水平来确定他汀类药物对炎症反应的影响(目的2A)。最近,他汀类药物被发现具有抗微生物作用。细菌感染是伤口愈合最常见的并发症之一,已知会抑制这一过程。因此,我们还将测试局部他汀类药物单独或与全身性他汀类药物组合是否加速细菌感染伤口的伤口愈合(目的2B)。拟议研究的高度影响是多因素的:1)它将提供一个经验证的体内实验模型,以研究与肥胖和高胆固醇水平相关的皮肤伤口愈合和感染; 2)为他汀类药物治疗伤口愈合障碍的潜在局部使用开发临床前证据,以及3)为他汀类药物可能影响全身使用患者伤口愈合能力的机制提供了新的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marjana Tomic-Canic其他文献
Marjana Tomic-Canic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marjana Tomic-Canic', 18)}}的其他基金
2023 Barrier Function of Mammalian Skin Gordon Research Conferences and Gordon Research Seminar
2023年哺乳动物皮肤屏障功能戈登研究会议及戈登研究研讨会
- 批准号:
10683587 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Micro-RNA Molecules as Regulators of Diabetic Wound Healing
Micro-RNA 分子作为糖尿病伤口愈合的调节剂
- 批准号:
8413654 - 财政年份:2012
- 资助金额:
$ 20.66万 - 项目类别:
Micro-RNA Molecules as Regulators of Diabetic Wound Healing
Micro-RNA 分子作为糖尿病伤口愈合的调节剂
- 批准号:
8519573 - 财政年份:2012
- 资助金额:
$ 20.66万 - 项目类别:
Micro-RNA Molecules as Regulators of Diabetic Wound Healing
Micro-RNA 分子作为糖尿病伤口愈合的调节剂
- 批准号:
8850720 - 财政年份:2012
- 资助金额:
$ 20.66万 - 项目类别:
The Role of Statins in Cutaneous Wound Healing
他汀类药物在皮肤伤口愈合中的作用
- 批准号:
8191602 - 财政年份:2011
- 资助金额:
$ 20.66万 - 项目类别:
Experimental Model For Pressure Ulcers In Human Skin: The Role of Aging and ECM
人类皮肤压疮的实验模型:衰老和 ECM 的作用
- 批准号:
7385171 - 财政年份:2008
- 资助金额:
$ 20.66万 - 项目类别:
Experimental Model For Pressure Ulcers In Human Skin: The Role of Aging and ECM
人类皮肤压疮的实验模型:衰老和 ECM 的作用
- 批准号:
7578219 - 财政年份:2008
- 资助金额:
$ 20.66万 - 项目类别:
Epidermal Genes and Their Regulators in Wound Healing
伤口愈合中的表皮基因及其调控因子
- 批准号:
6784615 - 财政年份:2003
- 资助金额:
$ 20.66万 - 项目类别:
Epidermal Genes and Their Regulators in Wound Healing
伤口愈合中的表皮基因及其调控因子
- 批准号:
7062107 - 财政年份:2003
- 资助金额:
$ 20.66万 - 项目类别:
Epidermal Genes and Their Regulators in Wound Healing
伤口愈合中的表皮基因及其调控因子
- 批准号:
6892862 - 财政年份:2003
- 资助金额:
$ 20.66万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 20.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)